Progress in the Study of Antibody-drug Conjugates for the Treatment of Cervical Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jun 21

PMID 38903711

Authors

Congcong Zhai

Yan Cui

Ling Guo

Cixiang Chen

Yanfang Song

Jinghua Zhong

Yili Wang

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is the second most prevalent malignancy affecting women's health globally, and the number of morbidity and mortality from cervical cancer continues to rise worldwide. The 5-year survival rate of patients with recurrent or metastatic cervical cancer is significantly reduced, and existing treatment modalities have low efficacy and high adverse effects, so there is a strong need for new, effective, and well-tolerated therapies. Antibody-drug conjugates (ADCs) are a new targeted therapeutic modality that can efficiently kill tumor cells. This review aims to summarize the composition, research, and development history and mechanism of action of ADCs, to review the research progress of ADCs in the treatment of cervical cancer, and to summarize and prospect the application of ADCs.

Citing Articles

The Role of Medical Therapies in the Management of Cervical Intraepithelial Neoplasia: A Narrative Review.

Rotar I, Boitor Borza D, Staicu A, Goidescu I, Nemeti G, Iulia P Medicina (Kaunas). 2025; 61(2).

PMID: 40005442 PMC: 11857687. DOI: 10.3390/medicina61020326.

References

Coleman R, Lorusso D, Gennigens C, Gonzalez-Martin A, Randall L, Cibula D . Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(5):609-619. DOI: 10.1016/S1470-2045(21)00056-5. View

Loganzo F, Tan X, Sung M, Jin G, Myers J, Melamud E . Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015; 14(4):952-63. DOI: 10.1158/1535-7163.MCT-14-0862. View

Birrer M, Moore K, Betella I, Bates R . Antibody-Drug Conjugate-Based Therapeutics: State of the Science. J Natl Cancer Inst. 2019; 111(6):538-549. DOI: 10.1093/jnci/djz035. View

Hisada Y, Mackman N . Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis. Semin Thromb Hemost. 2019; 45(4):385-395. PMC: 6546519. DOI: 10.1055/s-0039-1687894. View

Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K . Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017; 11:2265-2276. PMC: 5546728. DOI: 10.2147/DDDT.S135571. View

Vergote I, Van Nieuwenhuysen E, OCearbhaill R, Westermann A, Lorusso D, Ghamande S . Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. J Clin Oncol. 2023; 41(36):5536-5549. PMC: 10730069. DOI: 10.1200/JCO.23.00720. View

Liao S, Wang B, Zeng R, Bao H, Chen X, Dixit R . Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug Dev Res. 2021; 82(8):1096-1110. DOI: 10.1002/ddr.21870. View

Hafeez U, Parakh S, Gan H, Scott A . Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020; 25(20). PMC: 7587605. DOI: 10.3390/molecules25204764. View

Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P . Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol. 2018; 234(5):5628-5642. DOI: 10.1002/jcp.27419. View

10.

Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X . Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021; 24(4):913-925. PMC: 8205919. DOI: 10.1007/s10120-021-01168-7. View

11.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

12.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K . Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017; 18(11):1512-1522. DOI: 10.1016/S1470-2045(17)30604-6. View

13.

Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N . Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep. 2020; 10(1):973. PMC: 6976591. DOI: 10.1038/s41598-020-58009-3. View

14.

Martin-Sabroso C, Lozza I, Torres-Suarez A, Fraguas-Sanchez A . Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics. 2021; 13(10). PMC: 8541375. DOI: 10.3390/pharmaceutics13101705. View

15.

Nejadmoghaddam M, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani A . Antibody-Drug Conjugates: Possibilities and Challenges. Avicenna J Med Biotechnol. 2019; 11(1):3-23. PMC: 6359697. View

16.

Mutlu L, Tymon-Rosario J, Harold J, Menderes G . Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer. Expert Rev Anticancer Ther. 2022; 22(6):633-645. DOI: 10.1080/14737140.2022.2075348. View

17.

Starodub A, Ocean A, Shah M, Guarino M, Picozzi Jr V, Vahdat L . First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clin Cancer Res. 2015; 21(17):3870-8. PMC: 4558321. DOI: 10.1158/1078-0432.CCR-14-3321. View

18.

Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T . The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019; 67(3):173-185. DOI: 10.1248/cpb.c18-00744. View

19.

Bouleftour W, Guillot A, Magne N . The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review. Mol Cancer Ther. 2022; 21(4):493-501. DOI: 10.1158/1535-7163.MCT-21-0846. View

20.

Jin Y, Schladetsch M, Huang X, Balunas M, Wiemer A . Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2021; 229:107917. PMC: 8702582. DOI: 10.1016/j.pharmthera.2021.107917. View